Get to know Dr. Hwang
My research is to understand how oxidative stress contributes irregular heartbeats and contractility dysfunction in heart diseases. Current predictors can identify patients who are at very high risk, but unfortunately, sudden death is the first manifestation of heart disease in up to half the victims. Conventional drug treatment has either no benefits or even increases the rate of deaths. Thus, I have studied to develop new approached to treat disease-related contractile dysfunction.
- B.S., M.E.d., Seoul National University (Korea)
- M.S., The University of Texas (Austin, TX)
- Ph.D., The University of Michigan (Ann Arbor, MI)
- Post-Doc, Vanderbilt University (Nashville, TN)
Publications and Other Scholarly Activities
Hwang HS et al. Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J Mol Cell Cardiol. 2015
Hwang HS, et al. Divergent Regulation of RyR2 Calcium Release Channels by Arrhythmogenic Human Calmodulin Missense Mutants. Circ Res. 201
Hwang HS, et al. Inhibition of Cardiac Ca2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2011
- 2009 Postdoctoral Fellowship, American Heart Association
- 2012 Scientist Development Grant, American Heart Association
- 2009 Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roden DM, Wilde AAM, Knollmann BC, Flecainide Prevents Catecholaminergic Polymorphic Ventricular Tachycardia in Mice and Humans. Nat Med.